Lansen Pharmaceutical Holdings Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Li Chen
Chief executive officer
US$765.0k
Total compensation
| CEO salary percentage | 69.5% |
| CEO tenure | 5.8yrs |
| CEO ownership | n/a |
| Management average tenure | 5.8yrs |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
Does Lansen Pharmaceutical Holdings (HKG:503) Have A Healthy Balance Sheet?
Sep 18
Is Lansen Pharmaceutical Holdings (HKG:503) Using Too Much Debt?
Mar 27Lansen Pharmaceutical Holdings (HKG:503) Has A Rock Solid Balance Sheet
Sep 27Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?
Dec 06Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?
Sep 04We're Not So Sure You Should Rely on Lansen Pharmaceutical Holdings's (HKG:503) Statutory Earnings
Dec 28
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | US$7m |
| Mar 31 2023 | n/a | n/a | US$8m |
| Dec 31 2022 | US$765k | US$532k | US$9m |
| Sep 30 2022 | n/a | n/a | US$7m |
| Jun 30 2022 | n/a | n/a | US$6m |
| Mar 31 2022 | n/a | n/a | US$4m |
| Dec 31 2021 | US$697k | US$553k | US$903k |
| Sep 30 2021 | n/a | n/a | -US$3m |
| Jun 30 2021 | n/a | n/a | -US$7m |
| Mar 31 2021 | n/a | n/a | US$41m |
| Dec 31 2020 | US$624k | US$490k | US$88m |
| Sep 30 2020 | n/a | n/a | US$99m |
| Jun 30 2020 | n/a | n/a | US$110m |
| Mar 31 2020 | n/a | n/a | US$64m |
| Dec 31 2019 | US$664k | US$461k | US$18m |
| Sep 30 2019 | n/a | n/a | US$6m |
| Jun 30 2019 | n/a | n/a | -US$6m |
| Mar 31 2019 | n/a | n/a | -US$3m |
| Dec 31 2018 | US$576k | US$368k | US$160k |
Compensation vs Market: Li's total compensation ($USD765.00K) is above average for companies of similar size in the Hong Kong market ($USD233.10K).
Compensation vs Earnings: Li's compensation has been consistent with company performance over the past year.
CEO
Li Chen (61 yo)
5.8yrs
Tenure
US$765,000
Compensation
Mr. Li Chen has been Chief Executive Officer and Executive Managing Director of Lansen Pharmaceutical Holdings Ltd since March 1, 2018. He has been General Manager in Alfa Wassermann China since July 2014....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive MD | 5.8yrs | US$765.00k | no data | |
| Finance Manager & Company Secretary | 4.5yrs | no data | no data | |
| Group Human Resources Director | 8yrs | no data | no data | |
| Head of Business Development | no data | no data | no data | |
| Head of Finance Management Centre | no data | no data | no data | |
| Head of the Group’s production & Operation Management Centre | no data | no data | no data |
5.8yrs
Average Tenure
50yo
Average Age
Experienced Management: 503's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive MD | no data | US$765.00k | no data | |
| Independent Non-Executive Director | 1.8yrs | US$31.00k | no data | |
| Independent Non-Executive Director | 5.2yrs | US$35.00k | no data | |
| Non-Executive Chairman | 6.8yrs | no data | 16.41% HK$ 123.2m | |
| Independent Non-Executive Director | 13.7yrs | US$35.00k | no data | |
| Independent Non-executive Director | 1.3yrs | US$10.00k | 0.034% HK$ 252.1k | |
| Non-Executive Director | 7.8yrs | US$431.00k | no data |
6.0yrs
Average Tenure
65yo
Average Age
Experienced Board: 503's board of directors are considered experienced (6 years average tenure).